Skip to main content

Table 2 Adverse events associated with the intralymphatic injections in the cohort for testing procedural safety (n = 32)

From: Intralymphatic immunotherapy with tyrosine-adsorbed allergens: a double-blind, placebo-controlled trial

  All subjects (94 injections) Active group (55 injections) Control group (39 injections) P-value
Local reactions
 Pain 12 (12.8) 9 (16.4) 3 (7.7) 0.178
 Itch 8 (8.5) 6 (10.9) 2 (5.1) 0.275
 Paresthesia 6 (6.4) 4 (7.3) 2 (5.1) 0.513
 Wheal 1 (1.1) 0 (0.0) 1 (1.8) 0.415
 Heat sensation 1 (1.1) 1 (1.8) 0 (0.0) 0.585
Systemic reaction
 Dyspnea 5 (5.3) 3 (5.5) 2 (5.1) 0.660
 Wheezing 5 (5.3) 3 (5.6) 2 (5.1) 0.660
 Chest discomfort 4 (4.3) 4 (7.3) 0 (0.0) 0.112
 Headache 3 (3.2) 2 (3.6) 1 (2.6) 0.628
 Chills 3 (3.2) 2 (3.6) 1 (2.6) 0.628
 Palpitation 2 (2.1) 2 (3.6) 0 (0.0) 0.340
 Urticaria 2 (2.1) 1 (1.8) 1 (2.6) 0.660
 Itchy eyes 2 (2.1) 0 (0.0) 2 (5.1) 0.170
 Itchy palms 1 (1.1) 1 (1.8) 0 (0.0) 0.585
 Abdominal discomfort 1 (1.1) 1 (1.8) 0 (0.0) 0.585
 Fever 1 (1.1) 1 (1.8) 0 (0.0) 0.585
 Rhinorrhea 1 (1.1) 0 (0.0) 1 (2.6) 0.415
 Postnasal drip 1 (1.1) 0 (0.0) 1 (2.6) 0.415
 Sneezing 1 (1.1) 0 (0.0) 1 (2.6) 0.415
Hypersensitivity reactions* 0.273
 Grade 0 (none) 88 (94.6) 52 (94.5) 36 (94.7)  
 Grade 1 (mild) 4 (4.3) 1 (1.8) 3 (7.7)  
 Grade 2 (moderate) 0 (0.0) 0 (0.0) 0 (0.0)  
 Grade 3 (severe) 1 (1.1) 1 (1.8) 0 (0.0)  
 Grade 4 (anaphylactic) 0 (0.0) 0 (0.0) 0 (0.0)  
  1. Data are shown in frequencies (%). *Hypersensitivity reactions were graded according to Müller's classification